NEW YORK, Jan 4 – Affymetrix has granted Genomic Solutions a non-exclusive license to commercialize low and medium density microarrays, the companies announced Thursday.
Under the agreement, Genomic Solutions will provide Affymetrix with fees and royalty payments on arrays it sells. Genomic Solutions plans to build upon its line of GeneMap microarrays to include human, mouse and rat array sets as well as arrays specific to diseases and biochemical pathways, a company statement said. Currently, Genomic Solutions only offers a cancer-based microarray.
" Genomic Solutions is pleased to be able to provide this license to our GeneMap array product customers," Shannon Richey, vice president of the genomic business unit at Genomic Solutions, said in a statement. " With this license agreement, Genomic Solutions is now well-positioned to provide a broader offering of cDNA and oligonucleotide arrays to the marketplace. “
Over 25 companies have licensed array technology from Affymetrix, which holds a sizeable portion of the intellectual property in the field.